Based on the prevailing concept of tumor angiogenesis that tumor growth is dependent on the capacity to acquire oxygen and nutrients through the blood supply, current anti-angiogenic therapeutic approaches are designed to disrupt this process to “starve” tumor cells by inhibiting the functional sprouting and assembly of abnormal tumor vessels using anti-angiogenic agents (i.e. anti-VEGFA Bevacizumab)38. Here, VEGFA is linked to neoplasm.